Jay Backstrom Net Worth

The estimated Net Worth of Jay T. Backstrom is at least $63.2 Million dollars as of 16 February 2024. Jay Backstrom owns over 11,614 units of Acceleron Pharma Inc stock worth over $63,039,941 and over the last 5 years he sold XLRN stock worth over $182,804. In addition, he makes $0 as Executive Vice President - Research and Development at Acceleron Pharma Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jay Backstrom XLRN stock SEC Form 4 insiders trading

Jay has made over 1 trades of the Acceleron Pharma Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently he sold 11,614 units of XLRN stock worth $182,804 on 16 February 2024.

The largest trade he's ever made was selling 11,614 units of Acceleron Pharma Inc stock on 16 February 2024 worth over $182,804. On average, Jay trades about 1,452 units every 0 days since 2020. As of 16 February 2024 he still owns at least 352,671 units of Acceleron Pharma Inc stock.

You can see the complete history of Jay Backstrom stock trades at the bottom of the page.

Jay Backstrom biography

Dr. Jay T. Backstrom M.D. serves as Executive Vice President - Research and Development of the Company. Jay Backstrom M.D joined Acceleron in December 2019 and is currently our Executive Vice President, Research and Development. Dr. Backstrom previously served as Chief Medical Officer of Celgene Corporation from April 2016 until November 2019. Prior to that he served as Senior Vice President, Clinical R&D and Regulatory Affairs at Celgene where he was responsible for the late stage clinical and regulatory programs across the Hematology & Oncology portfolio. Dr. Backstrom joined Celgene in March 2008 as Vice President, Clinical R&D after serving as Vice President, Global Medical Affairs and Safety for Pharmion from 2002 to 2008. Prior to joining Pharmion, Dr. Backstrom was with Marion Merrell Dow and its successor companies including Hoechst Marion Roussel. Dr. Backstrom received his M.D. from Temple University School of Medicine. He did his post graduate training in Internal Medicine at Temple University Hospital and earned an M.S. in Public Health from Saint Louis University School of Public Health.

How old is Jay Backstrom?

Jay Backstrom is 65, he's been the Executive Vice President - Research and Development of Acceleron Pharma Inc since 2019. There are no older and 10 younger executives at Acceleron Pharma Inc.

Insiders trading at Acceleron Pharma Inc

Over the last 11 years, insiders at Acceleron Pharma Inc have traded over $211,038,855 worth of Acceleron Pharma Inc stock and bought 4,435,573 units worth $172,392,007 . The most active insiders traders include Corp /De/ Celgene, Richard F Pops und Anthony B Evnin. On average, Acceleron Pharma Inc executives and independent directors trade stock every 10 days with the average trade being worth of $7,646,210. The most recent stock trade was executed by Adam M Veness on 9 November 2021, trading 4,500 units of XLRN stock currently worth $132,165.

What does Acceleron Pharma Inc do?

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Complete history of Jay Backstrom stock trades at Acceleron Pharma Inc und Scholar Rock Corp

Acceleron Pharma Inc executives and stock owners

Acceleron Pharma Inc executives and other stock owners filed with the SEC include:

• Habib Dable,
  President, Chief Executive Officer, Director
• Kevin McLaughlin,
  Chief Financial Officer, Senior Vice President, Treasurer
• Sujay Kango,
  Executive Vice President and Chief Commercial Officer
• Ravindra Kumar,
  Senior Vice President, Chief Scientific Officer
• Francois Nader,
  Independent Chairman of the Board
• Joseph Zakrzewski,
  Independent Director
• Terrence Kearney,
  Independent Director
• Thomas McCourt,
  Independent Director
• Karen Smith,
  Independent Director
• Todd James,
  Senior Vice President Corporate Affairs and Investor Relations
• Kemal Malik,
  Independent Director
• Christopher Hite,
  Director
• Laura Hamill,
  Director
• Jay Backstrom,
  Executive Vice President - Research and Development
• Terrance Mcguire,
  Director
• Tom Maniatis,
  Director
• Jean George,
  Director
• John L Knopf,
  CEO and President
• Steven D Ertel,
  SVP & Chief Business Officer
• Matthew L Sherman,
  SVP & Chief Medical Officer
• Richard F Pops,
  Director
• Adam M Veness,
  SVP, General Counsel and Sec.
• John D Quisel,
  EVP, Chief Business Officer
• Christopher Rovaldi,
  SVP, Program Mgmt and Ops
• Robert K Zeldin,
  EVP & Chief Medical Officer
• Corp /De/ Celgene,
  10% owner
• Anthony B Evnin,
  Director
• Edwin M Jr Kania,
  Director
• Venture Management Co Iv Ll...,
  
• Venture Management Co Iv Ll...,
  
• Advisors Llcorbimed Capital...,
  
• Corp /De/Bristol Myers Squi...,